Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Effect of MEF2A and SLC22A3-LPAL2-LPA gene polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients

  • Laith N. AL-Eitan ,

    Roles Conceptualization, Data curation, Funding acquisition, Methodology, Project administration, Resources, Writing – review & editing

    lneitan@just.edu.jo

    Affiliation Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, Jordan

    ⨯
  • Ayah Y. Almasri,

    Roles Data curation, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing

    Affiliation Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, Jordan

    ⨯
  • Adan H. Alnaamneh,

    Roles Data curation, Investigation, Methodology, Validation, Writing – original draft, Writing – review & editing

    Affiliation Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, Jordan

    ⨯
  • Ahmad Mihyar

    Roles Writing – review & editing

    Affiliation Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, Jordan

    ⨯

Abstract

Aims

This study aims to investigate the influence of MEF2A and SLC22A3-LPAL2-LPA polymorphisms on cardiovascular disease susceptibility and responsiveness to warfarin medication in Jordanian patients, during the initiation and maintenance phases of treatment.

Backgrounds

Several candidate genes have been reported to be involved in warfarin metabolism and studying such genes may help in finding an accurate way to determine the needed warfarin dose to lower the risk of adverse drug effects, resulting in more safe anticoagulant therapy.

Methods

The study population included 212 cardiovascular patients and 213 healthy controls. Genotyping of MEF2A and SLC22A3-LPAL2-LPA polymorphisms was conducted to examine their effects on warfarin efficiency and cardiovascular disease susceptibility using PCR-based methods.

Results

One SNP (SLC22A3-LPAL2-LPA rs10455872) has been associated with cardiovascular disease in the Jordanian population, whereas the other SNPs in the MEF2A gene and SLC22A3-LPAL2-LPA gene cluster did not have any significant differences between cardiovascular patients and healthy individuals. Moreover, SLC22A3-LPAL2-LPA rs10455872 was correlated with moderate warfarin sensitivity, the other SNPs examined in the current study have not shown any significant associations with warfarin sensitivity and responsiveness.

Conclusion

Our data refer to a lack of correlation between the MEF2A polymorphism and the efficacy of warfarin treatment in both phases of treatment, the initiation, and maintenance phases. However, only rs10455872 SNP was associated with sensitivity to warfarin during the initiation phase. Furthermore, rs3125050 has been found to be associated with the international normalized number treatment outcomes in the maintenance phase.

Citation: AL-Eitan LN, Almasri AY, Alnaamneh AH, Mihyar A (2023) Effect of MEF2A and SLC22A3-LPAL2-LPA gene polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients. PLoS ONE 18(11): e0294226. https://doi.org/10.1371/journal.pone.0294226

Editor: Asem Surindro Singh, University of Cincinnati, INDIA

Received: January 1, 2023; Accepted: October 29, 2023; Published: November 10, 2023

Copyright: © 2023 AL-Eitan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: This project was supported by the Deanship of Research at Jordan University of Science and Technology under grant number (203/2014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Anticoagulant therapy has increasingly been used in the treatment and prevention of several cardiovascular diseases and thrombotic disorders [1, 2], where these anticoagulant drugs work by keeping the international normalized ratio (INR) within the target range. INR, a measure of thrombotic status, must remain within the therapeutic range to prevent any thrombotic complications, where the lower INR is related to an increased risk of thrombosis or stroke, while the higher INR is related to an increased risk of bleeding [3].

Warfarin (3-(α-acetonylbenzyl)-4-hydroxycoumarin) is the most well-known anticoagulant drug that has been prescribed for therapeutic purposes for six decades for its efficacy in the treatment and prevention of several thrombotic disorders such as thrombosis, atrial fibrillation and after orthopaedic surgery [3, 4]. Warfarin work by deactivating the vitamin K epoxide reductase C complex (VKORC1), therefore, inhibiting the reproduction of vitamin K reduced form, which decreases the activity of coagulation factors II, VII, IX, and X [5]. Warfarin efficacy and safety mainly depend on the maintenance of the INR within the target range. However, the warfarin dosage is determined by a trial-and-error approach until reaching the appropriate dose and the target INR, which increases the risk of adverse drug effects at the beginning stage of treatment [6, 7], where a lower or higher dosage than demanded could cause to thrombotic risk and bleeding, respectively [8]. The wide inter-individual variability in warfarin responsiveness may be explained due to age, gender, smoking status, body mass index, dietary vitamin K content, concomitant diseases such as impaired liver function, and heart failure, and the use of concomitant medications [9–12], in addition to inter-individual genetic variation [13, 14].

Several studies have found that there are at least 30 genes that modulate warfarin response and sensitivity [15]. Genetic variants of the VKORC1 and CYP2C9 genes were considered the most important polymorphisms that correlated with variability in warfarin dose and the time required to obtain the target INR [16–18]. However, several genes have been found to affect different cardiovascular disorders, such as the SLC22A3-LPAL2-LPA gene cluster [19], and some of these genes considered disease-causing genes such as the myocyte enhancer factor 2A (MEF2A) gene [20], a member of the MEF2 family, together with MEF2B, MEF2C, and MEF2D encodes the transcription factors that control the expression of numerous muscle-specific genes. However, in several studies, polymorphisms within this gene have been linked to Coronary Artery Disease (CAD) and Myocardial Infarction (MI) [21, 22]. SLC22A3-LPAL2-LPA gene cluster consists of three genes: solute carrier family 22 member 3 (SLC22A3) gene, lipoprotein(a)-like 2 (LPAL2) gene, and lipoprotein(a) (LPA) gene, located on chromosome 6q26-27 [23]. This gene cluster was identified by Tre´gouet et al. as a significant risk factor locus for CAD by a genome-wide haplotype association (GWHA) study [19, 24]. The LPA gene within this cluster expresses the apolipoprotein(a) segment of the Lp(a) lipoprotein particle, which make this cluster involved with cardiovascular diseases by impacting the plasma lipid levels. SLC22A3 gene that encodes organic cation transporter 3 (OCT3), playing a significant role in the transporting and clearance of toxic substances of many drugs, including metformin and histamine [25, 26], and several studies confirmed an association between SLC22A3 polymorphisms and the increased susceptibility to cardiovascular diseases [27, 28]. MEF2A and SLC22A3-LPAL2-LPA have been studied widely in their correlation with cardiovascular diseases in multiple ethnicities and have been both identified as risk factors for cardiovascular diseases [19, 21, 29, 30]. Genetic screening for multiple polymorphisms in Jordanian cardiovascular disease patients has been studied for multiple genes that are reported with warfarin responsiveness [31–34], however there is no record of studies that corelate MEF2A and SLC22A3-LPAL2-LPA with warfarin responsiveness in Jordanian cardiovascular disease patients. Increasing candidate genes that undergo warfarin pharmacodynamics and pharmacokinetics and studying their impacts on warfarin efficacy may help to find a precise way to adjust the appropriate dose of warfarin and reduce the risk of adverse drug reactions, resulting in more safe anticoagulant therapy. Therefore, the objective of this study is to investigate the impacts of the MEF2A and SLC22A3-LPAL2-LPA SNPs on warfarin treatment efficacy during the initiation and maintenance phases of treatment in Jordanian cardiovascular patients for the first time.

Materials and methods

Study design and subjects

The Human Ethics Committees of the Jordan University of Science and Technology and the Royal Medical Service in Jordan have confirmed this study Confirmation code: 13/78/2014. After providing information on the purpose of the study and giving written informed consent from both healthy and patient blood donors, 212 cardiovascular patients were selected from the Queen Alia Heart Institute (QAHI) (anticoagulation clinic) in Amman, Jordan, and 213 healthy control subjects characterized by being between 18 to 85 years old and did not have heart disease were enrolled in this study. All subjects fitted the following inclusion criteria; the participants were (50% female and 50% male) 18-year-old or older patients who have been receiving warfarin as an anticoagulant drug for at least three months and have regularly attended the anticoagulant clinic. While patients who had lack medical data or did not provide their written consent, alcoholics, pregnant women, or taking any warfarin-interacting medications were excluded from the study. These interacting medications have been determined based on Dutch standards for the treatment of coumarin interactions [35].

Firstly, 350 cardiovascular patients were analyzed, and 138 were excluded from the study due to the inclusion and exclusion criteria, incomplete treatment plan, and failure of genotyping as described by AL-Eitan et al. [34]. Only 139 cardiovascular patients from the remaining 212 patients achieved the maintenance phase of treatment.

Data collection and follow-up time

All medical and demographic data were gathered during the patient’s clinical visits. as described by Al-Eitan et al. [36].

SNP selection and genotyping

MEF2A gene codes for a transcription factor that is solely expressed in coronary atrial endothelial cells. Reports have corelated a 7 amino acid deletion mutation in exon11 this transcription factor with coronary artery diseases along with other missense mutations in this gene [30]. The SLC22A3-LPAL2-LPA gene cluster majorly contributes to the concentrations of Lipoprotein (a) in the body, which has been identified as a risk factor for developing coronary artery diseases [37]. The LPA gene in the cluster is responsible for the production of the apolipoprotein (a) component in the lipoprotein [38]. Multiple reports have corelated SNPs in the gene cluster and high lipoprotein (a) concentration with risk of cardiovascular diseases [38, 39]. Therefore, a total of 11 SNPs in MEF2A and SLC22A3-LPAL2-LPA genes were selected from public databases like National Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm. nih.gov/SNP) and the Applied Biosystems SNP database (http://www.appliedbiosystems). More information about the polymorphisms is listed in (S1 Table in S1 File). DNA was extracted from the blood samples using the commercially available Wizard Genomic DNA Purification Kit (Promega) according to the manufacturer’s instructions. Genotyping was carried out at the Australian Genome Research Facility (AGRF) by using the Mass ARRAY system (iPLEX GOLD). The primers information is available in (S2 Table in S1 File) used for the MEF2A, and SLC22A3-LPAL2-LPA genes and the Mass ARRAYTM system outcomes are available in (S1-S3 Figs in S1 File) [32].

Outcome measure

The warfarin dosage and INR values were collected from the patient’s medical records, in two different phases, the first was at the beginning of therapy where the warfarin dose and INR values are unstable, and this phase is called the initial phase of treatment. In this phase, all the patients follow the Royal Medical Services (RMS) Anticoagulation protocol by starting their warfarin treatment with 2.5 to 10mg doses taken at night on a daily bases. Older patients or patients with higher INR could be subject to lower doses as per the protocol. The second phase is called the maintenance phase of treatment, in which the warfarin dose is determined to be the mean value of the weekly dose at which the patient’s INR is stable and remains within the therapeutic range for two consecutive visits.

Warfarin sensitivity and responsiveness measure

Both sensitivity and responsiveness were monitored throughout the study by monitoring the warfarin daily intake dose prescribed that would keep the INR value within the borders the treatment range. After the initiation of the treatment, the patients’ medical record were used along with personal interviews to identify the dose of warfarin the patients take to maintain their INR values.

Patients in this study were classified into three groups based on warfarin sensitivity depending on Gordon’s (2009) study [40]:

  1. Warfarin resistance or poor metabolizer group, where the high daily dose of warfarin is needed to maintain the INR value within the treatment range (warfarin required dose> 49 mg/week).
  2. Warfarin response or moderate metabolizer group, where moderate warfarin doses were needed (Warfarin required dose between 21 and 49 mg/week).
  3. Warfarin sensitive or extensive metabolizer group, where the low warfarin doses were needed. (Warfarin required dose < 21 mg/week).

Furthermore, patients were classified into three groups based on warfarin responsiveness depending on Higashi et al. (2002) study [41]:

  1. Good responders’ group, with INR values among the therapeutic range.
  2. Poor responders’ group, with INR values below the therapeutic range.
  3. Extensive responders’ group, with INR values over the therapeutic range.

Statistical analysis

Microsoft Excel was used to calculate discrepancy and call rates, while the Pearson χ2 test was applied to estimate the aberration from Hardy Weinberg Equilibrium (HWE). For the genetic distribution, the Minor Allele Frequencies (MAF) and the Hardy-Weinberg equilibrium -p values were obtained using the Court lab-HW calculator. To find out which of the candidate SNPs is related to warfarin sensitivity and responsiveness, several statistical analyses were conducted, including the Chi-square test, unidirectional analysis of variance, and Turkey HSD post hoc multiple comparison tests. SPSS version 21.0 was utilized to conduct all analyses.

Multiple testing corrections

The effective number of SNPs was evaluated according to the published literature [35], Moreover, Bonferroni correction was conducted at α/n where α = 0.05 and n represents the number of SNPs [36].

Results

Study population

The study group consists of 212 warfarin intake patients and was used to evaluate the effect of MEF2A and SLC22A3-LPAL2-LPA SNPs on the warfarin efficiency during the initiation phase of treatment. The age of the participants ranged between 18 to 85, mean age (±SD) of 56.03±17.68. A total of 139 patients achieved the maintenance phase. Therefore, they were used to evaluate the effect of these polymorphisms on warfarin treatment during the maintenance phase.

Overall, there were 25 extensive responders (18.0%), 88 moderate responders (63.3%), and 26 poor responders (18.7%). The clinical and demographic characteristics of each of the three groups were collected and summarized in a previous study by Al-Eitan et al. [34]. All 7 SNPs examined in this study, except rs2048327 SNP of the SLC22A3-LPAL2-LPA gene cluster were following with the HWE. All the 7 SNPs were polymorphic and therefore non were excluded from the study. The 7 polymorphic SNPs have passed quality-control tests with high accuracy and a low degree of discrepancy. The minor alleles and their frequencies for the successful genotyped SNPs are shown in (S3 Table in S1 File).

Polymorphism frequencies of MEF2A and SLC22A3-LPAL2-LPAgenes and susceptibility between patients and control

Genotypic and allelic frequencies of MEF2A and SLC22A3-LPAL2-LPA genes in cardiovascular patients and healthy controls are shown in Table 1. Only rs10755578 SNP of the SLC22A3-LPAL2-LPA gene cluster ((CC+CG)/GG) was different significantly among patients and healthy controls (P = 0.04). Moreover, no significant associations were found between MEF2A and SLC22A3-LPAL2-LPA haplotypes and cardiovascular disease among patients and healthy controls (P ˃ 0.05) (S4 Table in S1 File).

thumbnail
Download:
Table 1. The distributions of MEF2A and SLC22A3-LPAL2-LPA SNPs in 212 cardiovascular patients and 213 healthy controls.

https://doi.org/10.1371/journal.pone.0294226.t001

Association of MEF2A and SLC22A3-LPAL2-LPA polymorphisms and warfarin sensitivity

Regarding the relationship between MEF2A and SLC22A3-LPAL2-LPA polymorphisms and warfarin sensitivity among the three inclusion groups (sensitive, moderate, and resistant), all SNPs showed no significant diversity among the warfarin-sensitive groups at the initiation phase of treatment (P ˃ 0.05) (Table 2). During the maintenance phase, a significant association was found between rs10455872 SNP of SLC22A3-LPAL2-LPA gene cluster and warfarin sensitivity (P = 0.02) (Table 3). Carriers of rs10455872 SNP (AA and GA) had a moderate sensitivity to warfarin. Furthermore, no significant correlation was remarked between MEF2A and SLC22A3-LPAL2-LPA haplotypes and sensitivity to warfarin (P ˃ 0.05) (S5 Table in S1 File).

thumbnail
Download:
Table 2. Association of MEF2A and SLC22A3-LPAL2-LPA polymorphisms with warfarin sensitivity during the initiation phase of therapy of 212 warfarin-treated cardiovascular patients.

https://doi.org/10.1371/journal.pone.0294226.t002

thumbnail
Download:
Table 3. Association of MEF2A and SLC22A3-LPAL2-LPA polymorphisms with warfarin sensitivity during the maintenance phase of therapy of 139 warfarin-treated cardiovascular patients.

https://doi.org/10.1371/journal.pone.0294226.t003

In the case of the association between MEF2A and SLC22A3-LPAL2-LPA SNPs and warfarin required dose, no significant correlation was noticed during the initiation and maintenance phases of treatment (P ˃ 0.05) (Table 4). The post-hock multiple comparisons test was conducted to test the significance of the warfarin required dose and MEF2A and SLC22A3-LPAL2-LPA SNPs. Moreover, the post-hock test revealed that there was no significant correlation between the studied SNPs and the warfarin required dose (P ˃ 0.05) (S6 Table in S1 File).

thumbnail
Download:
Table 4. Association of MEF2A and SLC22A3-LPAL2-LPA polymorphisms with variability on warfarin required doses.

https://doi.org/10.1371/journal.pone.0294226.t004

Association of MEF2A and SLC22A3-LPAL2-LPA polymorphisms and warfarin responsiveness

Based on the association of MEF2A and SLC22A3-LPAL2-LPA polymorphisms and warfarin responsiveness among the three warfarin response groups (poor, good, and extensive responders), there were no significant differences between MEF2A and SLC22A3-LPAL2-LPA polymorphisms either in the initiation phase or maintenance phase of therapy (P ˃ 0.05) (Tables 5 and 6). However, a significant association was found between ACCAGCTC SLC22A3-LPAL2-LPA haplotype and responsiveness to warfarin (P = 0.005) (S7 Table in S1 File). Among all warfarin intake patients, no significant differences were found regarding MEF2A and SLC22A3-LPAL2-LPA polymorphisms and initial INR values (P ˃ 0.05) (S8 Table in S1 File). In contrast, a significant difference was observed between rs3125050 SLC22A3-LPAL2-LPA SNP and the INR values measured during the maintenance phase of treatment (P = 0.02; Table 7).

thumbnail
Download:
Table 5. Association of MEF2A and SLC22A3-LPAL2-LPA polymorphisms with warfarin responsiveness during the initiation phase of therapy of 212 warfarin-treated cardiovascular patients.

https://doi.org/10.1371/journal.pone.0294226.t005

thumbnail
Download:
Table 6. Association of MEF2A and SLC22A3-LPAL2-LPA SNPs with warfarin responsiveness during the maintenance phase of therapy of 139 warfarin-treated cardiovascular patients.

https://doi.org/10.1371/journal.pone.0294226.t006

thumbnail
Download:
Table 7. Association of MEF2A and SLC22A3-LPAL2-LPA polymorphisms with INR treatment outcome.

https://doi.org/10.1371/journal.pone.0294226.t007

Discussion

Warfarin is the most broadly used anticoagulant drug, despite it being complicated by high variability in dose among individuals, requiring regular clinic visits and repeating INR tests [5, 42]. Various genetic and environmental factors affect the dose prescribed and the individual response to warfarin [9, 13]. More than 30 genes were found to associate with warfarin efficiency [15]. Numerous studies have investigated the correlation between various gene families polymorphisms and variability in warfarin dose and time required to arrive at the therapeutic INR in Jordanians and other ethnicities [13, 14, 17, 34, 36, 43, 44]. However, there is no report stating the correlation between MEF2A and SLC22A3-LPAL2-LPA polymorphisms in Jordanian cardiovascular disease patients and warfarin responsiveness. Studying more genes may help in finding an accurate prediction of therapeutic response and safety before the prescription. Therefore, new genes (MEF2A and SLC22A3-LPAL2-LPA) were analyzed in this study to determine their effects on warfarin sensitivity and responsiveness.

MEF2A gene has a highly polymorphic genomic sequence, which added interest to be studied and analyzed [45]. In fact, various studies have confirmed the association of MEF2A polymorphisms with the autosomal dominant Coronary Artery Disease (adCAD1) and Myocardial Infarction (MI) [21, 46, 47], and the belief that approximately 2% of CAD is a result of mutations in the MEF2A gene [29], especially, the mutations within exon 11, where various insertion/deletion and substitution polymorphisms like a common variant (CAG)n polymorphism [48, 49]. On the other hand, various studies have identified MEF2 polymorphisms in healthy people, therefore increasing the probability that this gene is not related to CAD [50]. Indeed, the association of MEF2A polymorphisms to CAD is controversial [50], Kajimoto et al. (2005) found that the MEF2A polymorphism is not contributed substantially to MI among the Japanese population [51], and Hsu et al. (2010) revealed that other Polymorphism in MEF2A is not linked to the Risk of CADin Taiwanese. Moreover, our study found that there is no significant association between MEF2Apolymorphism and cardiovascular diseases among Jordanian patients (Table 1).

Several studies have determined the SLC22A3-LPAL2-LPA cluster as a powerful susceptibility region for CAD [19]. Where other studies found there is no association of SLC22A3-LPAL2-LPA polymorphisms with cardiovascular diseases. Ahani et al. found a lacking of rs10755578 SNP within this gene cluster with CAD in the Iranian population [52], and another study by Lv et al. Also found that there is no association between SLC22A3-LPAL2-LPA polymorphisms and CAD in the Chinese Han population [23]. The genotypic and allelic frequencies of the studied SNPs in this study did not significantly differ between patients and healthy subjects except for one SNP. We found rs10755578 SNP is associated with cardiovascular diseases in Jordanian patients (Table 1), supposedly because of its ability to control plasma lipid levels. This result is incompatible with Ahani et al. study, which may be due to the different lifestyles and other environmental factors between the two populations, in addition to possibly presenting other polymorphisms that impact the diseases.

Our study exhibited that the allelic frequencies of the SLC22A3-LPAL2-LPA polymorphisms were found to be drastically different from other populations [52, 53]. For instance, the frequency of wild genotype (CC) of rs10755578 SNP in the cardiovascular patients was 41.8% in our population and 29.0% in the Iranian population, and 46.5% was the frequency of heterozygous genotype (CG) in our population and 40.0% in Iranian population, and the frequency of the mutant genotype (GG) was 19.0% and 31.0% in Jordanian and Iranian, respectively [52].

To our knowledge, no studies illustrate the correlation between MEF2A and SLC22A3-LPA L2-LPA polymorphisms and warfarin efficiency. In the current study, we examine the relationship between MEF2A and SLC22A3-LPAL2-LPA SNPs and warfarin sensitivity and responsiveness throughout the initiation and maintenance phases of treatment in Jordanian cardiovascular patients. Our results strongly indicate that there is no significant correlation between MEF2A and SLC22A3-LPAL2-LPA polymorphisms and their haplotypes and warfarin sensitivity and the warfarin required doses during the initiation and maintenance phases of treatment. (P ˃ 0.05) (Tables 2–4). Only SLC22A3-LPAL2-LPA rs10455872 SNP exhibited a significant correlation with sensitivity to warfarin during the maintenance phase. Our results showed that this SNP is linked to moderate sensitivity of warfarin during the maintenance phase, where we found that 64.2% of moderate patients were homozygous (AA) for this SNP and 0.0% of them were heterozygous (GA), which revealed that there is a significantly different with totalP = 0.02 (Table 3). The current study also showed that there is no significant relation between MEF2A and SLC22A3-LPAL2-LPA polymorphisms and responsiveness to warfarin during the initiation and maintenance phases of treatment (P ˃ 0.05) (Tables 5 and 6). There is only one haplotype block of the SLC22A3-LPAL2-LPA gene cluster (ACCAGCTC) revealed a significant relation with responsiveness to warfarin (P = 0.005). Besides, no significant differences were reported in our study regarding the INR measurements at the initiation phase of treatment with (P ˃ 0.05), On the other hand, there was a significant difference regarding the maintenance INR measurements with rs3125050 SLC22A3-LPAL2-LPA SNP with a (P = 0.02; Table 7).

Conclusion

In the current study, we assessed the genotypic and allelic frequencies of the MEF2A and SLC22A3-LPAL2-LPA SNPs in the Jordanian population and then studied whether these polymorphisms influence the response and sensitivity to warfarin at the initiation and maintenance phases of treatment. We conclude that the carrying of MEF2A or SLC22A3-LPAL2-LPA SNPs is not linked to warfarin dose, sensitivity, or responsiveness, except SLC22A3-LPAL2-LPA rs10455872 SNP that impact warfarin sensitivity during the maintenance phase. Moreover, SLC22A3-LPAL2-LPA rs3125050 SNP is associated with the maintenance INR values during the maintenance phase. It is worth to note that there is a lack of studies in regards of the pharmacogenomic treatment options in the Arab region including Jordan [54, 55]. Thus, we recommend that this study must be verified in larger sample sizes and other populations; in order to find more accurate anticoagulant therapy based on personalized medicine.

Acknowledgments

The authors would like to thank Jordan University of Science and Technology for providing logistic and technical support to the study.

References

  1. 1. Borges J.B., et al., Polymorphisms in genes encoding metalloproteinase 9 and lymphotoxin-alpha can influence warfarin treatment. Journal of Pharmacogenomics & Pharmacoproteomics, 2015. 6(1): p. 1.
  2. 2. Bader L.A. and Elewa H., The impact of genetic and non-genetic factors on warfarin dose prediction in MENA region: a systematic review. PloS one, 2016. 11(12): p. e0168732. pmid:27992547
  3. 3. Ansell J., et al., Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2008. 133(6): p. 160S–198S.
  4. 4. Natarajan S., et al., Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients. Pharmacological Reports, 2013. 65(5): p. 1375–1382. pmid:24399734
  5. 5. Yin T. and Miyata T., Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1—rationale and perspectives. Thrombosis research, 2007. 120(1): p. 1–10. pmid:17161452
  6. 6. Linkins L.-A., Choi P.T., and Douketis J.D., Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Annals of internal medicine, 2003. 139(11): p. 893.
  7. 7. Gage B.F. and Lesko L.J., Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. Journal of thrombosis and thrombolysis, 2008. 25(1): p. 45–51. pmid:17906972
  8. 8. Kim Y., Smith A., and Wu A.H., C3435T polymorphism of MDR1 gene with warfarin resistance. Clinica Chimica Acta, 2013. 425: p. 34–36. pmid:23872171
  9. 9. Hirsh J., et al., Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 2001. 119(1): p. 8S–21S. pmid:11157640
  10. 10. Visser L.E., et al., The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. British journal of haematology, 2004. 127(1): p. 85–89. pmid:15384981
  11. 11. Ansell J., et al., The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004. 126(3): p. 204S–233S. pmid:15383473
  12. 12. Veenstra D.L., et al., Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenetics and genomics, 2005. 15(10): p. 687–691. pmid:16141794
  13. 13. AL-Eitan L., Almasri A., and Khasawneh R., Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy. Genes, 2018. 9(12): p. 578. pmid:30486437
  14. 14. Al-Eitan L.N., Almasri A.Y., and Al-Habahbeh S.O., Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy. Pharmacogenomics and personalized medicine, 2019. 12: p. 1. pmid:30679919
  15. 15. Hughes D.A. and Pirmohamed M., Warfarin Pharmacogenetics. 2007, Springer.
  16. 16. Schwarz U.I., et al., Genetic determinants of response to warfarin during initial anticoagulation. New England Journal of Medicine, 2008. 358(10): p. 999–1008. pmid:18322281
  17. 17. Li C., et al., Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood, 2009. 113(17): p. 3925–3930. pmid:19074728
  18. 18. Takeuchi F., et al., A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS genetics, 2009. 5(3): p. e1000433. pmid:19300499
  19. 19. Trégouët D.-A., et al., Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nature genetics, 2009. 41(3): p. 283–285. pmid:19198611
  20. 20. González P., et al., The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. Journal of medical genetics, 2006. 43(2): p. 167–169. pmid:15958500
  21. 21. Wang L., et al., Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science, 2003. 302(5650): p. 1578–1581. pmid:14645853
  22. 22. Akazawa H. and Komuro I., Roles of cardiac transcription factors in cardiac hypertrophy. Circulation research, 2003. 92(10): p. 1079–1088. pmid:12775656
  23. 23. Lv X., et al., Lack of association between four SNPs in the SLC22A3-LPAL2-LPA gene cluster and coronary artery disease in a Chinese Han population: a case control study. Lipids in health and disease, 2012. 11(1): p. 128.
  24. 24. Craddock N.J. and Jones I.R., Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007. 447: p. 661–678.
  25. 25. Chen L., et al., Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenetics and genomics, 2010. 20(11): p. 687. pmid:20859243
  26. 26. Sakata T., et al., Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. Journal of pharmacological sciences, 2010. 113(3): p. 263–266. pmid:20562519
  27. 27. Shaw S.Y., et al., Genetic and clinical correlates of early-outgrowth colony-forming units. Circulation: Cardiovascular Genetics, 2011. 4(3): p. 296–304. pmid:21493818
  28. 28. Li L., et al., A solute carrier family 22 member 3 variant rs3088442 G→ A associated with coronary heart disease inhibits lipopolysaccharide-induced inflammatory response. Journal of Biological Chemistry, 2015. 290(9): p. 5328–5340.
  29. 29. Bhagavatula M.K., et al., Transcription factor MEF2A mutations in patients with coronary artery disease. Human molecular genetics, 2004. 13(24): p. 3181–3188. pmid:15496429
  30. 30. Omidi S., Ebrahimzadeh F., and Kalayinia S., 9P21. 3 locus; An important region in coronary artery disease: a panel approach to investigation of the coronary artery disease etiology. Int J Cardiovasc Pract, 2019. 4(2): p. 21–35.
  31. 31. Alghamdi M.A., et al., Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease. International Journal of General Medicine, 2021: p. 1093–1100. pmid:33790638
  32. 32. Al-Eitan L.N., et al., Influence of CYP4F2, ApoE, and CYP2A6 gene polymorphisms on the variability of Warfarin dosage requirements and susceptibility to cardiovascular disease in Jordan. International journal of medical sciences, 2021. 18(3): p. 826. pmid:33437219
  33. 33. Al-Eitan L.N., et al., Influence of SH2B3, MTHFD1L, GGCX, and ITGB3 Gene Polymorphisms on theVariability on Warfarin Dosage Requirements and Susceptibility to CVD in the Jordanian Population. Journal of Personalized Medicine, 2020. 10(3): p. 117. pmid:32916786
  34. 34. Al-Eitan L.N., Almasri A.Y., and Khasawneh R.H., Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy. Saudi Pharmaceutical Journal, 2019. 27(4): p. 484–490. pmid:31061616
  35. 35. Anonymous, Standaard Afhandeling Cumarine Interacties. 2003.
  36. 36. Al-Eitan L.N., Almasri A.Y., and Al-Habahbeh S.O., Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease. Pharmacogenomics and personalized medicine, 2019. 12: p. 15–22. pmid:30962704
  37. 37. Collaboration E.R.F., Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA: the journal of the American Medical Association, 2009. 302(4): p. 412.
  38. 38. Wang L., et al., Functional variant in the SLC22A3-LPAL2-LPA gene cluster contributes to the severity of coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016. 36(9): p. 1989–1996. pmid:27417586
  39. 39. Clarke R., et al., Genetic variants associated with Lp (a) lipoprotein level and coronary disease. New England Journal of Medicine, 2009. 361(26): p. 2518–2528. pmid:20032323
  40. 40. Consortium I.W.P., Estimation of the warfarin dose with clinical and pharmacogenetic data. New England Journal of Medicine, 2009. 360(8): p. 753–764. pmid:19228618
  41. 41. Higashi M.K., et al., Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama, 2002. 287(13): p. 1690–1698. pmid:11926893
  42. 42. D’Andrea G., D’Ambrosio R., and Margaglione M., Oral anticoagulants: Pharmacogenetics: Relationship between genetic and non-genetic factors. Blood reviews, 2008. 22(3): p. 127–140. pmid:18234403
  43. 43. Ibdah R.K., et al., Impact of PCSK9, WDR12, CDKN2A, and CXCL12 polymorphisms in Jordanian cardiovascular patients on warfarin responsiveness and sensitivity. International Journal of General Medicine, 2021: p. 103–118. pmid:33488114
  44. 44. Al-Eitan L.N., et al., Influence of PSRC1, CELSR2, and SORT1 gene polymorphisms on the variability of warfarin dosage and susceptibility to cardiovascular disease. Pharmacogenomics and Personalized Medicine, 2020: p. 619–632. pmid:33235484
  45. 45. Liu Y., et al., Variants in exon 11 of MEF2A gene and coronary artery disease: evidence from a case-control study, systematic review, and meta-analysis. PloS one, 2012. 7(2): p. e31406. pmid:22363637
  46. 46. Iida A., et al., Identification of 46 novel SNPs in the 130-kb region containing a myocardial infarction susceptibility gene on chromosomal band 6p21. Journal of human genetics, 2003. 48(9): p. 476–479. pmid:12920609
  47. 47. Hartiala J., et al., Genetic contribution of the leukotriene pathway to coronary artery disease. Human genetics, 2011. 129(6): p. 617–627. pmid:21293878
  48. 48. Guella I., et al., Association and functional analyses of MEF2A as a susceptibility gene for premature myocardial infarction and coronary artery disease. Circulation: Cardiovascular Genetics, 2009. 2(2): p. 165–172. pmid:20031581
  49. 49. Elhawari S., et al., A study of the role of the myocyte-specific enhancer factor-2A gene in coronary artery disease. Atherosclerosis, 2010. 209(1): p. 152–154. pmid:19782985
  50. 50. Weng L., et al., Lack of MEF2A mutations in coronary artery disease. The Journal of clinical investigation, 2005. 115(4): p. 1016–1020. pmid:15841183
  51. 51. Kajimoto K., et al., Assessment of MEF2A mutations in myocardial infarction in Japanese patients. Circulation Journal, 2005. 69(10): p. 1192–1195. pmid:16195615
  52. 52. Ahani M., et al., LACK OF ASSOCIATION BETWEEN RS10755578 POLYMORPHISMS OF LIPOPROTEIN (A) GENE AND CORONARY ARTERY DISEASE IN IRANIAN POPULATION. Acta Medica, 2015. 31: p. 1421.
  53. 53. Song Z.-K., et al., The association between the LPA gene polymorphism and coronary artery disease in Chinese Han population. BioMed research international, 2014. 2014. pmid:24790998
  54. 54. N Al-Eitan L. and A Haddad Y., Emergence of pharmacogenomics in academic medicine and public health in Jordan: History, present state and prospects. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), 2014. 12(3): p. 167–175.
  55. 55. N AL-Eitan L. and H Tarkhan A., Practical challenges and translational issues in pharmacogenomics and personalized medicine from 2010 onwards. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), 2016. 14(1): p. 7–17.